Ken Ham's Unwavering Belief That Science Bows to the Authority of Scripture
On this episode of the
Lighthouse Faith podcast, Ham doubles down on his conviction in the
authority of the Bible in all things, and yes, even science. For instance,
Ham says that regardless of what science has discovered about light may
not be the complete picture of its inimitable qualities. The Bible says
God created light, 'And God said, 'Let there be light.'' But what God
didn't tell us in Genesis is of light's wave/particle duality, or that the
speed of light is 671 million miles per hour. Ham is a scientist; one who
looks at the exact same data as any other trained expert. The difference is
that, because of his belief in the authority of the Bible, Ham's conclusions
diverge from conventional scientific thought.
Learn more about your ad choices. Visit podcastchoices.com/adchoices
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
'Sleeping giant' fault beneath Canada could unleash a major earthquake, research suggests
When you buy through links on our articles, Future and its syndication partners may earn a commission. A major fault in the Yukon, Canada, that has been quiet for at least 12,000 years may be capable of giving off earthquakes of at least magnitude 7.5, new research suggests. Based on the amount of strain the Tintina fault has accumulated over the past 2.6 million years, it is now under an amount of stress that could lead to a large quake within a human lifespan, researchers reported July 15 in the journal Geophysical Research Letters. The finding may require experts to rethink the earthquake danger in the region, the study authors said. An magnitude 7.5 earthquake would threaten a few small communities within the remote Yukon. But the finding that the Tintina fault may be capable of such a large quake is notable because the fault has been quiet since before the last ice age ended. "Major ancient faults like that can remain as weak zones in the Earth's crust and then focus ongoing tectonic strain," Theron Finley, a geoscientist who conducted the research while earning his doctorate at the University of Victoria in Canada, told Live Science. The Tintina fault is over 620 miles (1,000 kilometers) long and stretches from northeast British Columbia through the Yukon and into Alaska. On its southern end, it connects to the Rocky Mountain Trench fault, which creates a huge valley through southern Canada and northern Montana. Forty million years ago, during the Eocene epoch, one side of the Tintina fault slid 267 miles (430 km) against the other at a rate of about half an inch (13 millimeters) each year. Today, the fault seems quiet, with only occasional small earthquakes of magnitude 3 to 4 in some sections. However, "there has always been a question of whether it's still a little bit active or still accumulating strain at a slower rate," Finley said. To find out, Finley and his colleagues used high-resolution satellite data and lidar imagery of the Yukon. Lidar is a type of laser measurement that allows for precise imaging of topography while ignoring vegetation — an important tool for an area blanketed with forest. With this imagery, the researchers looked for signs on the surface of ancient earthquakes, such as fault "scarps," where the ground moved sharply upward on one side of the fault. "Those features can be hundreds of kilometers long in some cases, but they're only on the order of a couple meters high or wide, so we need the really high-resolution topographic data," Finley said. The researchers determined the dates of each rumple of the landscape by using traces left by incursions of glaciers, which occurred at known intervals 12,000 years ago, 132,000 years ago, and 2.6 million years ago. They found that over 2.6 million years, the fault's sides moved relative to each other by about 3,300 feet (1,000 m). Over the past 136,000 years, the opposing sides of the fault moved about 250 feet (75 m). It probably took hundreds of earthquakes to accumulate all that movement, Finley said, which translates to between 0.008 and 0.03 inches (0.2 to 0.8 mm) per year. The fault has not had a large earthquake that ruptured the ground surface for at least 12,000 years, according to the study. The researchers estimate that in that period, the fault has accumulated about 20 feet (6 m) of built-up strain — movement that hasn't yet been released in an earthquake. The fault probably breaks at between 3 and 33 feet (1 to 10 m) of strain, Finley said, so it's in the range where it might normally fracture. "It could still be many thousands of years before it reaches the threshold where it ruptures, but we don't know that and it's very hard to predict that," Finley said. Because the fault is active in its Alaska portion, it's not surprising to learn that the Tintina fault could be a sleeping giant, said Peter Haeussler, a geologist emeritus at the U.S. Geological Survey in Alaska. He said he was glad to see the evidence emerge."Somebody's finally found evidence for activity on the Tintina fault in the Yukon," Haeussler told Live Science. RELATED STORIES —There's a massive fault hiding under America's tallest mountain —Mystery magma reservoir found in volcanoless region of Alaska —Seattle's massive fault may result from oceanic crust 'unzipping itself' 55 million years ago "It ups the seismic hazard for this neck of the woods a little bit," he added, but not enormously, as the region was already known to be seismically active. The fault runs near Dawson City, Canada, Finley said, which has a population of about 1,600 and would be most threatened by a large quake. There are also mining facilities in the area, as well as a risk of quake-triggered landslides. To better understand the risk, geoscientists will need to excavate trenches in the fault to look for rock layers that show past earthquakes and how often they occurred. "Right now, we just know that many have occurred, but we don't have a sense of how frequently," Finley said. "Is 6 meters a lot of strain, or is it more likely there's a long way to go before another rupture?"
CBS News
4 hours ago
- CBS News
Capturing the melting of glaciers, with data and art
In the rugged North Cascade Mountains of Washington State, no one likely knows this glacier better than Mauri Pelto, who says, "My life has been shaped by this ice." For more than 40 years, Pelto, a glaciologist and a professor at Nichols College in Massachusetts, has returned to this remote wilderness. "We got 6,000 measurements on this glacier," he said. Today, the crunch of footsteps in the snow is now rivaled by the sound of melting ice. "It's always melting off," he said. "The crevasses are changing. We can hear the water flowing under our feet." Pelto founded the North Cascade Glacier Climate Project as a grad student in 1984. He vowed to measure these glaciers every summer for 50 years. This is Year 42. In that time the glaciers have changed more than he has, shrinking by 40%. Some have disappeared. Pelto's work has been featured by NASA, and fed into a worldwide glacier database. Of the 47 glaciers he has studied, returning to them year after year, he says 12 are now gone, "nine of them just in the last five years." Climate scientists say warmer summers and drier winters, driven by our burning of fossil fuels, are accelerating the loss. Seven of the 10 worst years for glacier melt worldwide have happened since 2010, according to Climate Central. Or just ask Mauri Pelto where the ice used to be. "Almost 50 feet above my head just a decade ago," he said. Glaciers are Earth's water towers, storing 70% of the freshwater supply, vital for drinking, farming, and the health of many ecosystems. As they melt, sea levels are rising, and coastal flooding is getting worse. During his annual treks to the North Cascades, Pelto has hiked nearly 6,000 miles, and slept 800 nights in a tent. "We got our picture window," he said of the view. "It's also one of those places that's really special to us as a family." His son Ben, daughter Jill, and now his nine-month-old granddaughter Wren have joined him in the field. Jill Pelto has spent 17 summers by her dad's side, but she doesn't just collect data. As the project's art director, she paints it. The data points that she and her dad measure eventually will go into her art. "Data is a story about something in the real world and that story has meaning and emotion," she said. "And that's what I'm trying to bring into my art." Her watercolor paintings are more than just beautiful landscapes; they reveal the science. Look closely and you see a bar graph of glacier decline in the North Cascades. One piece showing temperature rise and ice loss made the cover of Time magazine. Jill said, "I think sometimes when people see data there's this instant reaction, and so it's not like the data is any different in my art, but something about that combination maybe gets people to kind of put down the wall of like, 'Oh, I can't understand this,' or 'You know, this is not something I'm interested in.'" I said, "The average person is not going to read a scientific report, but they will see a painting. And it does impact you in a different way." "Yes, definitely," said Jill. Her art has given her dad a new way to share the story he's been recording for the past 42 years. And it's also changed their relationship: "We do it so seamlessly at this point," Mauri said. "Feels like you're one team out here?" I asked. "Yeah," he replied. Jill added, "This bigger project just means so much to us and has shaped our lives. So, sharing that year after year is beyond special." And now, Mauri Pelto has just eight summers left to fulfill his 50-year promise. Asked what he thinks it will be like to no longer come out to the glaciers, Mauri replied, "I don't know, I can't remember what it was like to not come out here. This landscape has been shaped by ice, and so to understand the landscape and the ice, you really have to walk across it." For more info: Story produced by Chris Spinder, in partnership with Climate Central. Editor: Chris Jolly. See also:
